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1. Introduction 
Phytochemicals found in foods and spices are progressively gaining popularity over 
conventional synthetic drugs mainly because they act via multiple molecular targets that 
synergize to efficiently prevent or treat chronic illnesses. Phytochemicals are also safe (with 
minimal or no toxic or side effects) with better bioavailability. Food saponins have been used 
in complimentary and traditional medicine against a variety of diseases including several 
cancers. Diosgenin, a naturally-occurring steroid saponin is found abundantly in legumes 
(Trigonella sp.) and yams (Dioscorea sp.). Diosgenin is a precursor of various synthetic steroidal 
drugs that are extensively used in the pharmaceutical industry. Over the past two decades, a 
series of pre-clinical and mechanistic studies have been independently conducted to 
understand the beneficial role of diosgenin against metabolic diseases (hypercholesterolemia, 
dyslipidemia, diabetes and obesity), inflammation and cancer. In experimental models of 
obesity, diosgenin decreases plasma and hepatic triglycerides and improves glucose 
homeostasis plausibly by promoting adipocyte differentiation and inhibiting inflammation in 
adipose tissues. A limited number of experiments have been conducted to understand the pre-
clinical efficacy of diosgenin as a chemopreventive/therapeutic agent against cancers of 
several organ sites. Mechanistic studies using in vitro models suggest that diosgenin 
suppresses cancer cell growth through multiple cell signaling events associated with 
proliferation, differentiation, apoptosis, inflammation and oncogenesis. This chapter 
provides a comprehensive review of the biological activity of diosgenin that contributes to 
several diseases in its role as a health beneficial phytochemical by citing new studies. In 
addition, diosgenin’s safety with regards to its potential toxicity is also critically discussed. 
Altogether, the findings from pre-clinical and mechanistic studies strongly implicate the use 
of diosgenin as a novel multi-target based chemopreventive or therapeutic agent against 
several chronic diseases. 
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1.1 Background of origin 
Diosgenin is a major bioactive constituent of various edible pulses and roots, well 
characterized in the seeds of fenugreek (Trigonella foenum graecum Linn) as well as in the root 
tubers of wild yams (Dioscorea villosa Linn) (No authors listed, 2004; Taylor et al., 2000). 
Reference to the ethnobotanical use of fenugreek seeds appears in the Egyptian Ebers 
papyrus (c. 1500 BC) as a medicine to induce childbirth. Fenugreek seeds were referred as a 
“soothing herb” by the Greek physician Hippocrates (5th century BC) and Dioscorides (1st 
century AD) suggested its use in the treatment of gynaecological inflammation (Chevalier, 
2000). Wild yam tubers on the other hand have been used traditionally as a pain reliever by 
the ancient Aztec and Mayan people in the Americas (Chevalier, 2000). Data available from 
various traditional medical practices indicate that fenugreek seeds and wild yam tubers 
have been purported to be used as a preventive or therapeutic medicine against several 
ailments including arthritis, cancer, diabetes, gastrointestinal disorders, high cholesterol, 
and inflammation suggesting a variety in its use (Memorial Sloan-Kettering Cancer 
Center). 
1.2 Chemistry, structure-function and bioavailability 
Structurally, diosgenin [(25R)-spirost-5-en-3b-ol] is a spirostanol saponin consisting of a 
hydrophilic sugar moiety linked to a hydrophobic steroid aglycone (Figure 1). Diosgenin is 
structurally similar to cholesterol and other steroids. Since its discovery, diosgenin is the 
single main precursor in the manufacture of synthetic steroids in the pharmaceutical 
industry (Djerassi et al., 1952). In a recent study it was shown that spirostanol compounds, 
especially diosgenin glycosides exhibited inducible or inhibitory activity in rat uterine 
contraction based on (a) the number, length and position of sugar side chains attached by a 
glycoside, and (b) related to the structure of the aglycone (Yu et al., 2010). The structure-
related functions of diosgenin have been extensively tested using cancer cells in vitro. In 
comparison to two-structurally-related saponins, hecogenin and tigogenin, only diosgenin 
caused a cell cycle arrest associated with strong apoptosis in vitro (Corbiere et al., 2003).) The 
biological activities of diosgenin and other structurally-related steroid saponins and 
alkaloids were tested in vitro (Trouillas et al., 2005). By using molecular modelling, the 
spatial conformation and electron transfer capacity were calculated in relation to the 
structural characteristics of diosgenin necessary to elicit its effect on proliferation rate, cell 
cycle distribution and apoptosis; and the anti-cancer bioactivity of diosgenin was shown to 
be related to the presence of a hetero-sugar moiety and the 5,6-double bond in its structure 
(Trouillas et al., 2005). Moreover, structural conformation at C-5 and C-25 carbon atoms was 
shown to be important for diosgenin’s biological activity (Trouillas et al., 2005). Further 
studies are warranted to assess the structure-function relationship of diosgenin and to 
understand whether and how synthetic changes brought about could augment its biological 
activity in favour of its role as a therapeutic agent. Rodent studies on the disposition of 
diosgenin revealed that diosgenin was poorly absorbed and underwent extreme 
biotransformation (Cayen et al., 1979). In the same study, 1 μg/mL of diosgenin was 
recovered from the serum of human subjects receiving an oral dose of 3 g diosgenin per day 
for 4 weeks suggesting poor absorption and possibly active biotranformation (Cayen et al., 
1979). 
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Fig. 1. Structure of diosgenin: Diosgenin (a) and its analogue protodioscin (b) are steroid 
saponins consisting of a hydrophilic sugar moiety linked to a hydrophobic steroid aglycone 
2. Metabolic diseases 
Fenugreek seeds and Dioscorea sp. yam tubers together with their constituent diosgenin 
have been shown to have biological activity against several metabolic diseases (Ulbricht et 
al., 2007; Raju & Rao, 2009). In the following sections, studies that have used the active 
constituent diosgenin in both experimental models of metabolic diseases and human clinical 
studies are reviewed. A list of studies evaluating the effects of diosgenin against different 
metabolic diseases is summarised in Table 1. 
 
Disease/ Effect  Experimental model Benificial 
potency 
Yes (Y) or
No (N)   
References 
Dyslipidemia/obesity    
Cholesterol-lowering
 
 
 
 
Adipocyte-
differentiation/  
inflammation 
Cholesterol-fed rats 
 
 
Cholesterol-fed chickens 
Cholesterol-fed rabbits  
Normal rats 
3T3-L1 (Mouse embryonic 
fibroblast - adipose like 
cells) 
Y 
 
 
Y 
Y 
N 
Y 
Cayen and Dvornik, 1979 
Juarez-Oropeza et al., 1987 
Son et al., 2007 
Cayen and Dvornik, 1979 
Cayen and Dvornik, 1979 
Cayen and Dvornik, 1979 
Uemura et al., 2010 
Diabetes    
Blood glucose 
 
Streptozotocin-induced 
diabetic rats 
Y McAnuff et al., 2005 
Liver function    
Cholestasis FVB mice 
Wistar rats 
 
NPC1L1-knockout (L1KO) 
and wild-type mice 
Y 
Y 
 
Y 
Kosters et al., 2005 
Nibbering et al., 2001 
Nervi et al., 1998 
Temel et al., 2009 
Table 1. Effect of diosgenin (purified) on metabolic and related diseases 
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2.1 Dyslipidemia and obesity 
The lipid-lowering potential of diosgenin has been demonstrated by several experimental 
studies (Sauvaire et al., 2000). Diosgenin decreased the elevated cholesterol in serum LDL 
and HDL fractions in cholesterol-fed rats, and had no effect on serum cholesterol in 
normocholesterolemic rats. In addition, diosgenin inhibited cholesterol absorption, and 
suppressed its uptake in serum and liver, and its accumulation in the liver (Cayen and 
Dvornik, 1979). Diosgenin lowered plasma cholesterol in diet-induced hypercholesterolemic 
rats, chicken and rabbits when administered orally or parenterally (Juarez-Oropeza et al., 
1987). Recently, it was shown that diosgenin ( at a oral dose of 0.1% or 0.5% in the diet for 
6 weeks) decreased total cholesterol levels and increased the plasma high-density 
lipoprotein (HDL) cholesterol level in both plasma and livers of diet-induced 
hypercholesterolemic rats (Son et al., 2007). In a study that evaluated the anti-obesity role 
of diosgenin-rich Dioscorea nipponica Makino, a related species to Dioscorea villosa, 
Sprague-Dawley rats fed a diet containing 40% beef tallow and 5% freeze-dried extract of 
the yam gained less body weight and adipose tissue than those that received only the 40% 
beef tallow diet (Kwon et al., 2003). In the same study it was shown that diosgenin 
suppressed the time-dependent increase of blood triacylglycerol levels when orally 
administered with corn oil to ICR mice, suggesting an inhibitory potential against fat 
absorption (Kwon et al., 2003). 
An evidence-based systemic review clearly suggests that fenugreek seeds (rich in diosgenin 
content) have an important role in the control of metabolic diseases such as diabetes and 
obesity (Ulbricht et al., 2007). Fenugreek decreased the size of adipocytes in diabetic obese 
KK-Ay mice suggesting an increased differentiation of adipocytes leading to decreased 
adipocyte lipid accumulation (Uemura et al., 2010). These results were further validated 
with molecular data that showed that fenugreek increased the mRNA expression levels of 
differentiation-related genes in adipose tissues (Uemura et al., 2010). Furthermore, in vitro 
experiments using 3T3-L1 adipocytes showed that diosgenin, the major saponin in 
fenugreek, promoted 3T3-L1 adipocyte differentiation to enhance insulin-dependent glucose 
uptake (Uemura et al., 2010). Two clinical studies were recently published showing the anti-
obesity properties of fenugreek seeds. First, a double-blind randomized placebo-controlled 
three-period (14 days) cross-over trial with twelve healthy male volunteers, demonstrated 
that fenugreek seed extract selectively reduced spontaneous fat consumption compared to 
placebo controls (Chevassus et al., 2009). However, there was no effect on body weight, 
normal and fasting glucose levels, insulin and lipid profile, and visual analogue scale scores 
of appetite/satiety in subjects receiving the fenugreek seed extract (Chevassus et al., 2009). 
In the second study, a 6-week double-blind randomized placebo-controlled parallel trial 
with thirty-nine healthy overweight male volunteers, showed decreased dietary fat 
consumption in subjects that received a fixed dose of a fenugreek seed extract compared to 
those that received the placebo (Chevassus et al., 2010). In addition, subjects that received 
the fenugreek seed extract also demonstrated a decrease in the insulin/glucose ratio in the 
serum of fasted subjects (Chevassus et al., 2010). Put together, these two clinical studies 
provided evidence to support that fenugreek seeds may potentially regulate fat 
consumption in humans. Whether diosgenin per se can mimic these results at appreciable 
doses in human subjects need to be addressed. 
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2.2 Diabetes 
There are several reports suggesting that diosgenin-rich food sources such as fenugreek seeds 
and yam tubers contribute to anti-diabetic effects in experimental models (Basch et al., 2003; 
Omoruyi, 2008). Evidence from human clinical trials clearly suggests that fenugreek seeds 
improve blood glucose and other metabolic parameters leading to treatment of diabetes (Basch 
et al., 2003).) Diosgenin significantly decreased plasma glucose in streptozotocin-induced 
diabetic rats by comparison to the diabetic controls suggesting its anti-diabetic properties 
(McAnuff et al., 2005). These results were further strengthened by the fact that several hepatic 
rate-limiting enzymes commonly involved in glucose metabolism altered in the diabetic state 
were normalized by treatment with diosgenin (McAnuff et al., 2005).  While there is ample 
evidence (including clinical trials) suggesting that fenugreek seeds may be used as an 
alternative medicine to treat diabetes and associated complications, more experimental studies 
are warranted to address if diosgenin can be efficaciously used in the control of diabetes and to 
understand the mechanism(s) of action. 
2.3 Liver function, liver disease and bile secretion 
There is a plethora of information that suggests that both fenugreek seeds and yam tubers 
influence several metabolic diseases directly affecting a number of molecular targets 
involved in enzyme metabolism as well as signal transduction pathways in the liver 
suggesting that their active compounds such as diosgenin may plausibly modulate liver 
function and may aid in the therapeutic control of liver diseases. A lyophilized fraction of 
Dioscorea sp. yam tubers attenuated CCl4-induced hepatic fibrosis in rats in a dose-
dependent manner (Chan et al., 2010). On the other hand, aqueous extract of fenugreek 
seeds contributed to a significant histopathological protection against ethanol-induced liver 
toxicity in rats (Thirunavukkarasu et al., 2003). Furthermore, the authors reported that this 
protection against ethanol-induced toxicity was by modulating lipid peroxidation and the 
antioxidant status (Thirunavukkarasu et al., 2003). Powdered fenugreek seeds administered 
in the diet at a dose of 5% (wt/wt) reduced the liver weight and alleviated hepatic steatosis 
in Zucker obese (fa/fa) rats (Raju and Bird, 2006).  The main mechanism of fenugreek seeds in 
controlling hepatic steatosis was through lowering plasma tumor necrosis factor (TNF)-α, a 
proinflammatory cytokine and by decreasing total fat and triglycerides in the liver (Raju and 
Bird, 2006). Specifically, there are no reports demonstrating the therapeutic potency of 
diosgenin against liver disease. It is postulated that diosgenin feeding causes cholesterol 
excretion in the stool of experimental animals, mainly by cholesterol secretion from the bile 
(Cayen and Dvornik, 1979). Diosgenin has been shown to increase cholesterol secretion five- 
to seven-fold in the bile of rats without altering the output of bile salts and phospholipids 
(Kosters et al., 2005; Nervi et al., 1988; Nibbering et al., 2001). Recently, it was shown that the 
bilary cholesterol secretion stimulated by diosgenin and leading to fecal cholesterol 
excretion is independent of intestinal cholesterol absorption (Temel et al., 2009). 
3. Cancer 
3.1 In vivo studies 
There are limited experimental studies addressing the in vivo tumor modulating potential of 
diosgenin (summarised in Table 2). Diosgenin inhibited the formation of colon aberrant 
crypt foci (ACF), putative precancerous lesions induced by azoxymethane (AOM) in F344 
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rats. In this study, administration of diosgenin in the diet at a dose of 0.1% and 0.05% 
(wt/wt) either during initiation/post-initiation or promotion stages significantly suppressed 
AOM-induced colon ACF (Raju et al., 2004). The demonstrated ability of diosgenin to inhibit 
both the total number of ACF and large ACF (those with crypt multiplicity of four or more) 
suggests that it could effectively prevent, retard and cease the appearance and growth of 
precancerous lesions in the colon (Raju et al., 2004). Furthermore the lower dose of 0.05% 
was as effective as the higher dose of 0.1% in blocking ACF formation (Raju et al., 2004). In a 
double-blind study designed to assess the tumor-modulating potential of diosgenin using 
the AOM-injected F344 rats, Malisetty et al. (2005) reported that 0.1% of diosgenin 
suppressed the incidence of both invasive and non-invasive colon adenocarcinomas by up to 
60% (Malisetty et al., 2005). In addition, diosgenin decreased colon tumor multiplicity 
(adenocarcinomas/rat) compared to Controls. In part, these in vivo effects were shown to be 
related to a lower proliferating cell nuclear antigen (PCNA) index in colon tumors 
suggesting that diosgenin attenuates tumor cell proliferation (Malisetty et al., 2005). 
 
Organ site 
Pathological target 
 Experimental model Inhibition*
Yes (Y) or 
No (N)  
References 
Colon    
Aberrant crypt foci 
Tumors 
Ulcers/tumors 
AOM-induced rats 
AOM-induced rats 
AOM/DSS-induced 
ICR mice 
Y 
Y 
Y 
Raju et al., 2004 
Malisetty et al., 2005 
Miyoshi et al., 2011 
Breast    
MCF-7 tumor xenografts 
MDA 231 tumor xenografts 
Nude (nu/nu) mice 
Nude (nu/nu) mice 
Y 
Y 
Srinivasan et al., 2009 
Srinivasan et al., 2009 
Lung    
LA795 ectopic tumors T739 mice Y Yan et al., 2009 
*Inhibition of either (a) tumor incidence [number of tumor-bearing animals], (b) tumor multiplicity 
[number of tumors per tumor-bearing rats], or (c) tumor size. 
Table 2. In vivo anticancer effects of diosgenin (purified) 
Diosgenin has been shown to attenuate inflammatory process in relevant animal models. 
For instance, diosgenin dose-dependently attenuated sub-acute intestinal inflammation and 
normalized bile secretion in indomethacin-induced intestinal inflammation in rats (Yamada 
et al., 1997). The role of chronic inflammation on carcinogenesis is vital (Dinarello, 2006); 
thus the study by Yamada et al. (1997) demonstrating the ability of diosgenin to effectively 
treat inflammation could be extrapolated to its prospective chemopreventive action against 
cancers. Recently, the efficacy of diosgenin against AOM/dextran sodium sulphate (DSS)-
induced inflammation-associated colon carcinogenesis in ICR mice was reported (Miyoshi N 
et al., 2011). Diosgenin at doses of 20, 100 and 500 mg/kg (wt/wt) in the diet reduced 
AOM/DSS induced ulcers to 53%, 46% and 40%, respectively in comparison to control 
(Miyoshi et al, 2011). While diosgenin did not alter the incidence of colon tumors (adenoma 
+ adenocarcinoma), it reduced the tumor multiplicity significantly at all the three tested 
doses (Miyoshi N et al., 2011). Furthermore, it was shown that diosgenin’s potency against 
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experimentally-induced inflammation-associated colon carcinogenesis was in part mediated 
by the alteration of lipid metabolism (reduced serum triglyceride levels by up-regulation of 
lipoprotein lipase), and the modulation of genes associated with inflammation and multiple 
signaling pathways (Miyoshi N et al., 2011). 
With regards to breast cancer, the effect of diosgenin on the ectopic growth of human breast 
cancer MCF-7 and MDA 231 tumor xenografts was studied in nude mice (Srinivasan et al., 
2009). It was reported that diosgenin (10 mg/kg body weight administered intra-tumorally) 
significantly inhibited the growth of tumor xenografts of both MCF-7 and MDA 231 
compared to vehicle-treated controls, with no toxicity to any of the vital organs in the 
experimental mice (Srinivasan et al., 2009). To test the anti-aging properties of diosgenin in 
relation to hormonal-effects in vivo, Tada et al. (2009) assessed the effect of diosgenin-rich 
Dioscorea Sp. yam tuber extract on the ectopic growth of estradiol-dependent human breast 
cancer (MCF-7) in ovarectomized nude mice for 12 weeks. Diosgenin containing extracts 
was shown to repress the size of the tumors compared to sham controls (Tada et al., 2009). 
Yan et al. (2009) reported that oral administration of diosgenin at a dose of 200 ppm (p.o.) 
significantly inhibited the growth mouse LA795 lung adenocarcinoma tumors by 33.94% in 
T739 inbred mice. 
3.2 In vitro studies 
The anti-cancer effects of diosgenin in vitro through different mechanisms are discussed in 
the following sub-sections. Many molecular candidates critical to tumorigenesis are affected 
by diosgenin (Raju and Mehta, 2009; Raju and Rao, 2009). The in vitro anticancer effects of 
diosgenin and its cellular/molecular effects is summarised in Table 3. 
3.2.1 Colon cancer 
Diosgenin inhibited the growth of HT-29 and HCT-116 human colon adenocarcinoma cells 
(Lepage et al., 2010; Raju and Bird, 2007; Raju et al., 2004). Diosgenin induced apoptosis in 
HT-29 cells, in part by inhibition of bcl-2 and by induction of caspase-3 protein expression 
(Raju et al., 2004). Lepage et al. (2010) reported that in HT-29 cells, diosgenin at 40 µM 
caused delayed apoptosis together with an increase in cyclooxygenase (COX)-2 expression 
and activity, higher 5-lipooxygenase (LOX) expression and enhanced leukotriene B4 
production. COX-2 inhibition by NS-398 strongly sensitized HT-29 cells to diosgenin-
induced apoptosis (Lepage et al., 2010). Furthermore, diosgenin was shown to sensitize HT-
29 cells to TRAIL-induced apoptosis (Lepage et al., 2011). In HCT-116 cells, diosgenin was 
shown to induce apoptosis by the cleavage of the 116 kDa poly (ADP-ribose) polymerase 
(PARP) protein to the 85kDa fragment (Raju and Bird, 2007). In addition, it was shown that 
diosgenin significantly lowered the expression of HMG-CoA reductase at both mRNA and 
protein levels, suggesting the involvement of the cholesterol biosynthetic pathway in 
diosgenin’s efficacy as an anti-cancer agent (Raju and Bird, 2007). 
3.2.2 Breast cancer 
Diosgenin arrested the growth of HER2 oncoprotein-overexpressing AU565 human breast 
adenocarcinoma cells at sub-G1 phase (Chiang et al., 2007). Selective apoptosis induced by 
diosgenin in these cells was found to be through PARP cleavage involving the down- 
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Organ site Cancer cell 
type 
Cellular/molecular targets References 
Colon HT-29 Apoptosis/ bcl-2, caspase-3, 
COX-2, 5-LOX 
Raju et al., 2004 
Lepage et al., 2010; 2011 
 HCT-116 Apoptosis/ PARP, COX-2, 5-LOX
Lipid metabolism/ HMG-CoA 
reductase 
Raju et al., 2007 
Lepage et al., 2010; 2011 
Raju et al., 2007 
Breast AU565 Apoptosis/ PARP, mTOR, JNK 
Lipid metabolism/FAS 
Chiang et al., 2007 
 MCF-7 Growth-proliferation/ Akt, p53 
Apoptosis/ NF-κB, Bcl-2, 
survivin 
Srinivasan et al., 2009 
 MDA 231 Growth-proliferation/ ERK 
Apoptosis/caspase-3, NF-κB, Bcl-
2, survivin 
Srinivasan et al., 2009 
Prostate PC-3 Growth-proliferation/ PI3K, Akt, 
ERK, JNK, NF-κB 
Angiogenesis/ VEGF 
Chen et al., 2011 
 DU145 Growth-invasion/ HGF, mdm2, 
vimentin, Akt, mTOR 
Chang et al., 2011 
Cervix CaSki Growth-proliferation Fernández-Herrera et al., 
2010 
Liver HCC Apoptosis/caspase-3, PARP 
Transcription/ STAT3, cSrc  
Li et al., 2010 
Bone/blood 1547 
osteosarcoma
Apoptosis/ NF-κB, p53, PPAR-γ, 
COX-2 
Corbiere et al., 2003; 2004a 
Moalic et al., 2001 
 RAW-264.7 Growth-proliferation/ NF-κB, 
RANK-L 
Shishodia and Aggarwal, 
2006 
 KBM-5 Growth-proliferation/ NF-κB, 
IκBα, cyclin-D1,  
Shishodia and Aggarwal, 
2006 
 HEL Apoptosis/ PARP, caspase-3, p21
Eicosanoid biosynthesis/ COX-2, 
5-LOX/cPLA2 
Leger et al., 2004a; 2006 
Leger et al., 2004b; Napez 
et al., 1995 
 K562 Apoptosis/ PARP, caspase-3, NF-
κB, COX-2, p38 MAPK 
Liagre et al., 2005 
Larynx HEp-2 Apoptosis/ p53 Corbiere et al., 2004b 
Skin M4Beu Apoptosis/ p53 Corbiere et al., 2004b 
Table 3. In vitro anticancer activities of diosgenin (purified) 
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regulation of phospho-Akt and phospho- mammalian target of rapamycin (mTOR), and up-
regulation of phospho- c-Jun N-terminal kinase (JNK) independent of p38 and extracellular 
signal regulating kinase (ERK) phosphorylations (Chiang et al., 2007). In the same cell-line 
(AU565 cells), diosgenin inhibited the expression of fatty acid synthase (Chiang et al., 2007). 
The anti-cancer mechanism of diosgenin was shown to be different in human breast cancer 
cells based on the status of estrogen receptor (ER) expression (Srinivasan et al., 2009). In ER-
positive MCF-7 human breast cancer cells, diosgenin induced p53 tumor suppressor protein; 
while the pro-apoptotic mechanism of diosgenin in ER-negative MDA human breast 
carcinoma cells involved the activation of caspase-3 and down-regulation of bcl-2 
(Srinivasan et al., 2009). 
3.2.3 Prostate cancer 
Diosgenin inhibited proliferation of PC-3 human prostate cancer cells in a dose-dependent 
manner (Chen et al., 2011). At non-toxic doses, diosgenin suppressed cell migration and 
invasion by reducing the activities and mRNA expression of matrix metalloproteinase (MMP) 
-2 and MMP-9 (Chen et al., 2011). Diosgenin abolished the expression of vascular endothelial 
growth factor (VEGF) in PC-3 cells and tube formation of endothelial cells (Chen et al., 2011). 
In addition, diosgenin downregulated the phosphorylation of phosphatidylinositide-3 kinase 
(PI3K), Akt, ERK and JNK proteins and significantly decreased the nuclear level of nuclear 
factor (NF)-κB, suggesting that diosgenin inhibited NF-κB activity (Chen et al., 2011). Another 
study using DU145 human prostate cancer cells found that diosgenin abrogated hepatocyte 
growth factor (HGF)-induced cell scattering and invasion, together with inhibition of Mdm2 
and vimentin through down-regulation of phosphorylated Akt and mTOR (Chang et al., 2011). 
3.2.4 Cervical cancer 
Recently, Fernández-Herrera et al. (2010) reported the synthesis of a novel 26-hydroxy-22-
oxocholestanic steroid from diosgenin and its anticancer activity against human cervical 
cancer CaSki cells. Mainly this diosgenin-derivative caused apoptosis at non-cytotoxic doses 
activation of caspase-3 along. Furthermore, they report that antiproliferative doses of this 
compound observed in cancer cells did not affect the proliferative potential of normal 
fibroblasts from cervix and peripheral blood lymphocytes (Fernández-Herrera et al., 2010). 
3.2.5 Liver cancer 
Diosgenin was shown to inhibit the proliferation of hepatocellular carcinoma (HCC) cells in 
a dose and time-dependent manner (Liu et al., 2005). Diosgenin caused arrest of HCC cells 
at the G1 phase of the cell cycle and induced apoptosis through caspase-3 activation leading 
to PARP cleavage (Li et al., 2010). In these cells, diosgenin inhibited both constitutive and 
inducible activation of signal transducers and activators of transcription (STAT)3 with no 
effect on STAT5, and suppressed the activation of c-Src, Janus-family tyrosine kinases 
(JAK)1 and JAK2 implicated in STAT3 activation (Li et al., 2010). 
3.2.6 Other cancers 
Cytotoxic effects of diosgenin were reported in human cancer cell lines of various other 
organ types: osteosarcoma (Corbiere et al., 2003, Moalic et al., 2001), leukemia (Liu et al., 
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2005) and erythroleukemia (Leger et al., 2004a). The growth of 1547 human osteosarcoma 
cells was inhibited through G1 phase cell cycle arrest and induction of apoptotic demise; and 
the main the mechanism involved the activation of p53 and binding of NFB to DNA 
independent of PPAR- (Corbiere et al., 2003, 2004a). Interestingly, diosgenin’s effect in 
suppressing osteoclastogenesis in RAW-264.7 cells was reported to follow a pro-apoptotic 
mechanism through receptor activated NFB ligand (RANK-L) induction (Shishodia and 
Aggarwal, 2006). Moalic et al. (2001) demonstrated that diosgenin inhibited COX-2 activity 
and expression in human osteosarcoma 1547 cells. 
Diosgenin arrested chronic myelogenous leukemia KBM-5 cells of human origin at sub-G1 
phase of cell cycle arrest (Shishodia and Aggarwal, 2006). This cell cycle arrest was 
correlated to the inhibition of tumor necrosis factor (TNF)-dependent NF-B activation and 
TNF-induced degradation and phosphorylation of IB (the inhibitory subunit of NF-B) 
(Shishodia and Aggarwal, 2006). Diosgenin downregulated TNF-induced cyclin D1 in KBM-
5 cells (Shishodia and Aggarwal, 2006). Furthermore it abolished both basal and TNF-
induced COX-2 gene products in a time-dependent manner (Shishodia and Aggarwal, 2006).  
Diosgenin controlled the growth of human erythroleukemia TIB-180 (HEL) cells by arresting 
cells at G2/M cell cycle and inducing apoptosis through PARP cleavage, activation of 
caspase-3 and up-regulation of p53-independent p21 (Leger et al., 2004a, 2004b, 2006). 
Diosgenin treatment to HEL cells induced cytosolic phospholipase (cPL)A2 activation 
through translocation to the cellular membrane together with an increase in COX-2 
expression (Leger 2004b).  In a study by Nappez et al. (1995), it was reported that diosgenin 
treatment in HEL cells did not affect 5-LOX mRNA or 5-LOX activating protein (FLAP) 
mRNA at the transcriptional level. However, when HEL cells undergoing differentiation 
were incubated with diosgenin in the presence of indomethacin (a COX inhibitor), the 
growth inhibitory effect of diosgenin was reversed and an exponential growth kinetic of 
undifferentiated cells was observed (Nappez et al., 1995). Taken together, these studies 
provide an insight into the role of 5-LOX in diosgenin’s modulation of growth and 
differentiation in HEL cells. Leger et al. (2004b) demonstrated that diosgenin increased the 
synthesis of arachidonic acid in HEL cells leading to COX-2 overexpression, which was 
accompanied by apoptosis induction. The anticancer activity of diosgenin was also shown in 
human erythroleukemia K562 cells through caspase-3-activation dependent PARP-mediated 
pro-apoptotic effects (Liagre et al., 2005). Diosgenin induced COX-2-independent apoptosis 
through activation of the p38 MAP kinase signalling pathway and inhibition of NFB 
binding in COX-2 deficient K562 cells (Liagre et al., 2005). The anticancer mechanism of 
diosgenin was also shown in laryngocarcinoma HEp-2 and melanoma M4Beu cells through 
a p53-dependent cell death meachnism (Corbiere et al., 2004b). 
4. Other diseases and ailments 
A clinical study by Turchan-Cholewo et al. (2006) reported that diosgenin may have 
therapeutic potential against an increased risk of developing dementia in opiate abusers 
with HIV infection. Recently, the effect of diosgenin on hepatitis C virus (HCV) replication 
was reported (Wang et al., 2011). Based on a reporter-based HCV subgenomic replicon 
system, diosgenin was found to inhibit HCV replication at low µM concentrations in vitro 
(Wang et al., 2011). Furthermore, a combination of diosgenin and interferon-α exerted an 
additive effect on the resultant anti-HCV activity (Wang et al., 2011). The neuroprotective 
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effect of diosgenin against d-galactose-induced senescence in mice by improving cognitive 
abilities as assessed through the Morris water maze test and mediated by enhancing 
endogenous antioxidant enzyme activities (Chiu et al., 2011). Diosgenin induced apoptosis 
in non-cancerous human rheumatoid arthritis synoviocytes (RAS) through the 
overexpression of COX-2 protein and concomitant increase in the level of prostaglandin 
(PG)-E2 (Liagre et al., 2004, 2007). Diosgenin may be an effective inhibitor of 
hyperpigmentation, commonly seen in skin disorders and inhibits melanogenesis by 
activating the PI3K pathway and (Lee et al., 2007). A novel effect of diosgenin in restoration 
of keratinocyte proliferation in aged skin in an animal model suggests that diosgenin may 
have a potential in slowing the aging process in the skin commonly associated with 
climacteric (Tada et al., 2009). Recent data support the possibility that some diosgenin-
glycoside derivatives may represent a new type of contractile agonist for the uterus and 
their synergism may be responsible for their therapeutic effect against abnormal uterine 
bleeding (Yu et al., 2010). 
5. Safety 
There is a claim that diosgenin has an endocrine effect (estrogen-like or progesterone-like 
activity) in humans, however there is no scientific evidence to its validation (Djerassi et al., 
1952; No authors listed, 2004). Diosgenin is neither synthesized nor metabolically converted 
into steroid by-products in the mammalian body. Toxicology studies using relevant 
experimental models have established that even at an upper concentration of 3.5% (wt/wt), 
diosgenin was safe and failed to cause systemic toxicity, genotoxicity, or estrogenic activity 
(63). Qin et al. (2009) reported that ethanol extracts of Dioscorea sp. containing 28.34% 
(wt/wt of lyophilized powder) did not cause any signs of acute toxicity in mice at an upper 
tested dose of 562.5 mg/kg/d, and did not significantly change toxicological parameters up 
to a dose of 255 mg/kg/d. No acute renal or hepatic toxicity associated with the 
administration of extracts of Dioscorea villosa at an oral dose of 0.79 g/kg/d (Wojcikowski et 
al., 2008). However, an increase in fibrosis in the kidneys and in inflammation in livers when 
rats were on the dose for 28 days was reported in the same study (Wojcikowski et al., 2008). 
Thus it was concluded that these toxicology effects be considered when consuming these 
extracts on a long-term basis, especially in people with compromised renal or hepatic 
function (Wojcikowski et al., 2008). On the other hand, in a 90-day subchronic study, rats fed 
fenugreek seeds, at doses between 1% and 10% in pure diet, had no toxic effects 
(Muralidhara et al., 1999). Typically, fenugreek seeds are known to contain ∼0.42% to 0.75% 
diosgenin depending on the cultivars and seed quality (Taylor et al., 2000). Fenugreek seed 
extract evaluated using the standard battery of tests (reverse mutation assay, mouse 
lymphoma forward mutation assay and mouse micronucleus assay) recommended by US 
Food and Drug Administration (FDA) for food ingredients came negative and thus rendered 
safe for consumption at the therapeutic doses tested (Flammang et al., 2004). A recent study 
using human sera indicated that fenugreek seed powder contains several proteins that 
potentially act as allergens (Faeste et al., 2009); however, it remains unclear if diosgenin in 
interaction with any proteins would test positive in these allergen tests. More studies are 
warranted to understand the toxicological effects of diosgenin at both levels present in 
common foods as well as therapeutic doses. Although there is toxicology data with regards 
to diosgenin-rich botanicals such as Dioscorea sp. yam tubers and fenugreek seeds, there is a 
clear lack of data studying the safety of diosgenin per se. Some of the important aspects for 
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future studies assessing the toxicology of diosgenin include those related to developmental 
toxicity, neurotoxicity and allergenicity. 
6. Conclusions 
With changing lifestyle patterns such as diet and physical activity combined with factors 
such as genetic predispositions and smoking, the incidences of metabolic diseases including 
diabetes and obesity and certain kinds of cancers are increasing worldwide and hence are a 
public health concern with major economic impacts. While the pathogenesis of these 
diseases is different, there appears to be one or more molecular candidates that are 
commonly up- or down-regulated leading to the notion that these could be common 
molecular targets in prevention or therapeutic interventions of diseases. Ethnomedicine has 
been instrumental in providing important clues as to the role herbs and foods and their 
bioactive constituents in disease prevention and therapy; however, rigorous experimental-
based evidence in support of ethnomedicine-derived notions would lead to the 
development of products relevant to and drug development. Several naturally-occurring 
compounds such as those in edible plants or spices are known to target multiple molecular 
pathways of signalling, thus bestowing them a broad preventive/therapeutic potential 
against several diseases. For example, curcumin from turmeric, resveratrol from grapes and 
epigallocatechin gallate (EGCG) from green tea have shown excellent pre-clinical potency 
against a wide range of diseases (reviewed in Epstein et al., 2010; Marques et al., 2009; Saito 
et al., 2009). These natural compounds have also been tested in clinical trials as potential 
therapeutics against several diseases. One emerging natural compound of interest with 
similar potency as curcumin, resveratrol and EGCG is diosgenin. In the above sub-sections, 
we have discussed in detail, the health promoting effects of diosgenin and diosgenin-rich  
 
Fig. 2. Schematic representation depicting the molecularmode of action of diosgenin in the 
control of metabolic pathway. Diosgenin plausibly regulates signaling molecules in fatty 
acid metabolism and inflammatory pathway. Insulin and IGF-1 mediated signalling 
pathways may also be regulated by diosgenin and are thus candidates for future studies 
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sources: (a) Dioscorea sp. yam tubers and (b) Trigonella sp. (fenugreek) seeds. In addition, we 
have summarised the toxicology data pertaining to the safe use of diosgenin either in a pure 
form (where data was available) or in extracts. The health promoting effects of diosgenin 
can be broadly divided according to the differential molecular mechanisms it elicits. First, 
there is a growing body of experimental evidence suggesting the use of diosgenin in the 
treatment of metabolic diseases. Much of this is rendered through diosgenin’s capacity to 
lower lipids in the blood and perhaps in tissues such as liver and adipose tissue. To date, 
there is some evidence that implicates both inflammatory pathway-associated NFκB and 
fatty acid metabolism-associated HMG-CoA reductase and FAS as potential molecular 
targets of diosgenin (Chiang et al., 2007; Raju and Bird, 2007), and these may be extended to 
its role as a therapeutic against metabolic diseases (Figure 2). Pathways associated with 
insulin and insulin-like growth factor (IGF)-1 may be of relevance in understanding the 
molecular mechanism of diosgenin’s action in the control of metabolic diseases (Figure 2). 
Second, the role of diosgenin in modulating cancers has been substantially addressed; most 
of these data are related to the growth and proliferation of human cancer cell types and its 
potential mechanism(s) of action in vitro. Several molecular candidates associated with fatty 
acid metabolism (Chiang et al., 2007; Raju and Bird, 2007), inflammatory pathway (Leger et 
al., 2006; Liagre et al., 2005; Shishodia and Aggarwal, 2006), eicosanoid biosynthesis (Leger 
et al., 2004; Lepage et al., 2010; 2011; Moalic et al., 2001; Napez et al., 1995), cell proliferation 
and growth (Chiang et al., 2007; Leger et al., 2006; Srinivasan et al., 2009), apoptosis 
(Corbiere et al., 2004; Leger et al., 2006; Lepage et al., 2010; 2011; Raju and Bird, 2007; Raju et 
al., 2004), and regulation of transcription (Chiang et al., 2007; Li et al., 2010) are affected (up- 
or down-regulated) by diosgenin leading to tumor cell death (Figure 3). 
 
Fig. 3. Schematic representation of plausible mechanism of action(s) of diosgenin at the 
cellular level as a cancer chemopreventivel/therapeutic agent. Diosgenin up- or down-
regulates several molecular candidates associated with cell proliferation and growth, 
apoptosis, regulation of transcription, fatty acid metabolism, inflammatory pathway and 
eicosanoid biosynthesis leading to tumor cell death. 
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While there are ample in vivo studies available to implicate the beneficial effects of diosgenin 
against metabolic disease, more studies to understand the specific modes of action at the 
molecular level are warranted. On the contrary, substantial in vitro evidence exists to 
understand the molecular mechanism of action of diosgenin against several cancers. More in 
vivo studies are thus essential to understand the physiological relevance of such data in 
controlling cancers. Moreover, there is excellent opportunity to address whether diosgenin 
plays a role in chemoprevention versus therapy, or both, in cancers of various organ sites 
using relevant models. The health beneficial effects of diosgenin are further extended to its 
potential role to treat other ailments such as HIV and hepatitis-C infections as well as liver 
diseases. There is little information regarding the bioavailability, pharmacokinetics and 
pharmacodynamics of diosgenin in relation to its health beneficial effects. Diosgenin and 
diosgenin-containing products are emerging in the market and are being promoted as 
natural health products. The scientific knowledge in this area is limited and hence extensive 
pre-clinical and clinical research should be carried out prior to advocating the safe and 
efficacious use of diosgenin and diosgenin-rich plant extracts against the prevention and 
control of diseases. Furthermore, such research will assist in the development of evidence-
based regulation of diosgenin and disogenin-containing products as they become 
increasingly popular and enter the market. 
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There are significant concerns regarding the potential side effects from the chronic use of conventional drugs
such as corticosteroids, especially in children. Herbal therapy is less expensive, more readily available, and
increasingly becoming common practice all over the world. Such practices have both their benefits and risks.
However, herbal self-therapy might have serious health consequences due to incorrect self-diagnosis,
inappropriate choice of herbal remedy or adulterated herbal product. In addition, absence of clinical trials and
other traditional safety mechanisms before medicines are introduced to the wider market results in
questionable safe dosage ranges which may produce adverse and unexpected outcomes. Therefore, the use
of herbal remedies requires sufficient knowledge about the efficacy, safety and proper use of such products.
Hence, it is necessary to have baseline data regarding the use of herbal remedies and to educate future
health professionals about various aspects of herbal remedies.
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